Neuroleptic Malignant Syndrome: An Undiagnosed Case
Volume 2 - Issue 5
Haris Chaudhry1*, Cesar Figueroa2, Mohammad Alasker2, Saher Aslam3, Usama Nasir4 and Ibrar Anjum5
-
Author Information
Open or Close
- 1Loma Linda University, Department of Surgery, USA
- 2University of California Irvine, Department of surgery, USA
- 3University at Buffalo, Catholic Health System, Department of Medicine, USA
- 4CMH Lahore Medical College and Institute of Dentistry, Department of Medicine, Pakistan
- 5The University of Texas MD Anderson Cancer Center, USA
*Corresponding author:
Haris Chaudhry, Loma Linda University, Department of Surgery Loma Linda, USA
Received: August 26, 2019; Published: September 04, 2019
DOI: 10.32474/SJPBS.2019.02.000147
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Neuroleptic malignant syndrome (NMS) was first described six decades ago after the introduction of neuroleptic drugs for the treatment of psychotic disorders [1]. NMS is an infrequent yet potentially fatal adverse effect of the neuroleptic class of antipsychotic medications. Signs of NMS include fever, muscular rigidity, altered mental status, elevation of creatine kinase (CK) with its incidence ranging between 0.07% to 0.2% [2-3]. NMS is possible with all neuroleptics. It can be easily recognized in its classic form but the lack of a specific diagnostic criteria along with its rare occurrence has limited further study in this field [4]. NMS is not generally considered dose-dependent and can occur within the therapeutic dose range of the antipsychotic drugs [5]. The frequency of NMS ranges from 0.07 to 2.2%. Its pathophysiology is not clearly understood but the blockade of dopamine receptors appears to be the central mechanism [6]
Background|
Objective|
Case Report|
Discussion|
Conclusion|
References|